MCID: INF023
MIFTS: 50

Inflammatory Breast Carcinoma

Categories: Rare diseases, Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Inflammatory Breast Carcinoma

MalaCards integrated aliases for Inflammatory Breast Carcinoma:

Name: Inflammatory Breast Carcinoma 12 14 69
Inflammatory Breast Cancer 50 52
Inflammatory Carcinoma of Breast 12
Inflammatory Breast Neoplasms 42
Breast Cancer, Inflammatory 50
Mastitis Carcinomatosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6263
MeSH 42 D058922
NCIt 47 C4001
SNOMED-CT 64 254840009
UMLS 69 C0278601

Summaries for Inflammatory Breast Carcinoma

NIH Rare Diseases : 50 inflammatory breast cancer (ibc) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. this type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or “inflamed.” the skin may also look dimpled like the skin of an orange. ibc can be difficult to diagnose because there is no lump to feel or detect on a mammogram. it is crucial to identify ibc right away because early diagnosis and treatment can greatly improve the outcome. patients are often given a combination of treatments, including chemotherapy, surgery, and radiation therapy. approximately one-third of individuals diagnosed with ibc will become long-term survivors. like other types of breast cancer, ibc can occur in men, but usually at an older age than in women. some studies have shown an association between family history of breast cancer and ibc, but more studies are needed to draw firm conclusions. last updated: 9/24/2015

MalaCards based summary : Inflammatory Breast Carcinoma, also known as inflammatory breast cancer, is related to bladder tuberculosis and nerve fibre bundle defect, and has symptoms including edema, pain and peau d'orange. An important gene associated with Inflammatory Breast Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are Development ERBB-family signaling and Endometrial cancer. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and testes, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased viability with paclitaxel

Wikipedia : 72 Inflammatory breast cancer is one of the most aggressive types of breast cancer that can occur in women... more...

Related Diseases for Inflammatory Breast Carcinoma

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ
Brip1-Related Breast Cancer

Diseases related to Inflammatory Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
id Related Disease Score Top Affiliating Genes
1 bladder tuberculosis 10.4 CDH1 ERBB2
2 nerve fibre bundle defect 10.3 ERBB2 ESR1
3 tumor of exocrine pancreas 10.3 EGFR ESR1
4 brenner tumor of the vagina 10.3 ERBB2 ESR1
5 brenner tumor of ovary 10.3 ERBB2 ESR1
6 infiltrating ureter transitional cell carcinoma 10.2 EGFR ERBB2
7 bartholin's gland benign neoplasm 10.1 ESR1 PGR
8 central nervous system organ benign neoplasm 10.1 ESR1 PGR
9 gallbladder leiomyoma 10.1 ESR1 PGR
10 lung adenoma 10.1 ESR1 PGR
11 fallopian tube benign neoplasm 10.1 ESR1 PGR
12 paranasal sinus disease 10.1 ESR1 PGR
13 dartoic leiomyoma 10.1 ESR1 PGR
14 urinary bladder inverted papilloma 10.1 ESR1 PGR
15 deafness, autosomal dominant 8/12 10.1 ESR1 PGR
16 intestinal perforation 10.1 ESR1 PGR
17 superficial basal cell carcinoma 10.1 ESR1 PGR
18 sarcomatoid squamous cell skin carcinoma 10.1 ESR1 PGR
19 bladder colloid adenocarcinoma 10.1 ESR1 PGR
20 ovarian mesodermal adenosarcoma 10.1 ESR1 PGR
21 endophthalmitis 10.1 ESR1 PGR
22 osteogenesis imperfecta 10.1 ESR1 PGR
23 chest wall lymphoma 10.1 ESR1 PGR
24 cutaneous mucoepidermoid carcinoma 10.1 ESR1 PGR
25 retinal detachment 10.1 ESR1 PGR
26 holoprosencephaly 6 10.1 ESR1 PGR
27 acute thyroiditis 10.1 ESR1 PGR
28 occupational dermatitis 10.1 EGFR ERBB2
29 retinitis pigmentosa 20 10.0 ESR1 PGR
30 urethra clear cell adenocarcinoma 10.0 ESR1 PGR
31 rectal neoplasm 10.0 ESR1 PGR
32 breast sarcoma 10.0 CDH1 ERBB2 ESR1
33 adenosine monophosphate deaminase 1 deficiency 10.0 ESR1 PGR
34 gorham's disease 10.0 EGFR ERBB2
35 perinatal jaundice due to hepatocellular damage 10.0 ESR1 PGR
36 thoracic benign neoplasm 10.0 ESR1 PGR
37 pancreatic somatostatinoma 10.0 CDH1 EGFR
38 large cell acanthoma 10.0 ESR1 PGR
39 breast signet ring cell adenocarcinoma 10.0 EGFR ERBB2
40 gastrointestinal system benign neoplasm 10.0 ESR1 PGR
41 uterine corpus apoplectic leiomyoma 9.9 ESR1 PGR
42 sohval soffer syndrome 9.9 EGFR ERBB2
43 gastritis 9.9 ERBB2 PGR
44 ampulla of vater neoplasm 9.9 ESR1 PGR
45 integumentary system cancer 9.9 CDH1 EGFR
46 extragonadal nonseminomatous germ cell tumor 9.9 EGFR PGR
47 lymphoma 9.9
48 mastitis 9.9
49 early congenital syphilis 9.9 EGFR ERBB2
50 hip subluxation 9.8 EGFR ERBB2 ESR1

Graphical network of the top 20 diseases related to Inflammatory Breast Carcinoma:



Diseases related to Inflammatory Breast Carcinoma

Symptoms & Phenotypes for Inflammatory Breast Carcinoma

UMLS symptoms related to Inflammatory Breast Carcinoma:


edema, pain, peau d'orange

GenomeRNAi Phenotypes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.43 CDH1 ERBB2 ESR1 FUT3 PGR PROX1
2 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
3 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Inflammatory Breast Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 CDH1 EGFR ERBB2 ESR1 PGR PROX1
2 digestive/alimentary MP:0005381 9.8 CDH1 EGFR ERBB2 ESR1 PROX1
3 endocrine/exocrine gland MP:0005379 9.8 EGFR ERBB2 ESR1 PGR PROX1 CDH1
4 embryo MP:0005380 9.77 CDH1 EGFR ERBB2 ESR1 PGR
5 integument MP:0010771 9.65 ESR1 PGR CDH1 EGFR ERBB2
6 muscle MP:0005369 9.46 EGFR ERBB2 ESR1 PGR
7 neoplasm MP:0002006 9.35 CDH1 EGFR ERBB2 ESR1 PGR
8 normal MP:0002873 9.17 CDH1 EGFR ERBB2 ESR1 PGR PROX1

Drugs & Therapeutics for Inflammatory Breast Carcinoma

Drugs for Inflammatory Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 271)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
3
Ketorolac Approved Phase 4,Phase 3 74103-06-3, 66635-83-4 3826
4
Butorphanol Approved, Illicit, Vet_approved Phase 4 58786-99-5, 42408-82-2 5361092
5
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
6
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
7
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
8 taxane Phase 4,Phase 3,Phase 1
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
10 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
11 glucocorticoids Phase 4,Phase 3
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Methylprednisolone acetate Phase 4
16 Methylprednisolone Hemisuccinate Phase 4
17 Neuroprotective Agents Phase 4
18 Prednisolone acetate Phase 4
19 Prednisolone hemisuccinate Phase 4
20 Prednisolone phosphate Phase 4
21 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Ketorolac Tromethamine Phase 4,Phase 3
29 Analgesics, Opioid Phase 4
30 Antitussive Agents Phase 4
31 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
33 Flurbiprofen axetil Phase 4
34 Narcotic Antagonists Phase 4
35 Narcotics Phase 4
36 Pharmaceutical Solutions Phase 4
37 Respiratory System Agents Phase 4
38 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
39 Psychotropic Drugs Phase 4,Phase 3,Phase 2
40
Serotonin Phase 4,Phase 3 50-67-9 5202
41 Serotonin Agents Phase 4,Phase 3
42 Serotonin Antagonists Phase 4,Phase 3
43 Tranquilizing Agents Phase 4,Phase 3,Phase 2
44 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 1,Early Phase 1
45
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
46
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
47
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
48
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
49 Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
50
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 204)

id Name Status NCT ID Phase Drugs
1 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
2 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
3 Comparison of Pain Therapeutic Effects After Benign Mastectomy Completed NCT00519246 Phase 4 Saline;Opioid;Opioid;NSAID;NSAID;Opioid;Opioid
4 Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers Withdrawn NCT02637466 Phase 4 Vortioxetine
5 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
6 Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer Unknown status NCT00003680 Phase 3 CMF regimen;cyclophosphamide;fluorouracil;methotrexate;tamoxifen citrate;thiotepa
7 Combination Chemotherapy in Treating Women With Breast Cancer Unknown status NCT00003679 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;tamoxifen citrate
8 Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer Unknown status NCT00397761 Phase 2, Phase 3 capecitabine;paclitaxel albumin-stabilized nanoparticle formulation
9 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
10 Perioperative Inflammation and Breast Cancer Outcome Unknown status NCT02141139 Phase 3 NSAIDS (ketorolac and ibuprofen)
11 Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Completed NCT02324088 Phase 3 Docetaxel;Cyclophosphamide;Epirubicin
12 Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer Completed NCT00017095 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
13 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
14 S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00016406 Phase 3 cyclophosphamide;doxorubicin;paclitaxel
15 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
16 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
17 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00475085 Phase 3 aprepitant;dexamethasone;granisetron hydrochloride;palonosetron hydrochloride;prochlorperazine;placebo
18 Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors Completed NCT00440089 Phase 2, Phase 3
19 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
20 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
21 Relaxation for Women With Breast Cancer Undergoing Radiotherapy Recruiting NCT01202851 Phase 3
22 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
23 Ketorolac in Breast Cancer Surgery Active, not recruiting NCT01806259 Phase 3 Ketorolac 30 mg IV
24 European Celecoxib Trial in Primary Breast Cancer Active, not recruiting NCT02429427 Phase 3 Celecoxib
25 A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer Active, not recruiting NCT01964391 Phase 3 Trastuzumab;Doxorubicin;Cyclophosphamide;Paclitaxel;Docetaxel;Carboplatin;Neo-adjuvant chemotherapy
26 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting NCT02131064 Phase 3 Carboplatin;Docetaxel;Pertuzumab;Trastuzumab;Trastuzumab Emtansine
27 Management of Insomnia in Breast Cancer Patients Active, not recruiting NCT01011218 Phase 2, Phase 3 Armodafinil;Placebo
28 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Terminated NCT00016276 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;cyclophosphamide;paclitaxel;tamoxifen citrate
29 Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy Terminated NCT00028704 Phase 3
30 Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery Unknown status NCT00251329 Phase 2 neoadjuvant chemotherapy
31 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
32 Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Unknown status NCT00002627 Phase 1, Phase 2 carboplatin;cyclophosphamide;mesna;paclitaxel
33 Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Unknown status NCT00398489 Phase 2 anastrozole;cyclophosphamide;docetaxel;epirubicin hydrochloride;goserelin acetate;tamoxifen citrate
34 Trastuzumab in Treating Older Women With Early-Stage Breast Cancer Unknown status NCT00796978 Phase 2
35 Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer Completed NCT00066443 Phase 1, Phase 2 docetaxel;epirubicin hydrochloride
36 Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Completed NCT00016549 Phase 2
37 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed NCT00558103 Phase 2 lapatinib;Pazopanib
38 Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer Completed NCT00105950 Phase 2 lapatinib
39 Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer Completed NCT01325428 Phase 2 Afatinib once daily (OD);Vinorelbine Weekly
40 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193050 Phase 2 Gemcitabine;Epirubicin;Docetaxel
41 Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer Completed NCT00111787 Phase 2 Lapatinib;Paclitaxel
42 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193206 Phase 2 Gemcitabine;Epirubicin;Albumin-bound Paclitaxel
43 Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer Completed NCT00256243 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;GM-CSF;Trastuzumab
44 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
45 Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer Completed NCT01206881 Phase 2 pegylated liposomal doxorubicin
46 Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Completed NCT00049114 Phase 2 doxorubicin hydrochloride;cyclophosphamide;tipifarnib
47 Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Completed NCT00070252 Phase 1, Phase 2 Capecitabine;Docetaxel;Tipifarnib
48 A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer Completed NCT00001193 Phase 2
49 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
50 Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer Completed NCT00004925 Phase 1, Phase 2 pegylated liposomal doxorubicin hydrochloride

Search NIH Clinical Center for Inflammatory Breast Carcinoma

Cochrane evidence based reviews: inflammatory breast neoplasms

Genetic Tests for Inflammatory Breast Carcinoma

Anatomical Context for Inflammatory Breast Carcinoma

MalaCards organs/tissues related to Inflammatory Breast Carcinoma:

39
Breast, Skin, Testes, Lung, Prostate, Liver, Colon

Publications for Inflammatory Breast Carcinoma

Articles related to Inflammatory Breast Carcinoma:

(show top 50) (show all 100)
id Title Authors Year
1
Diffuse dermal angiomatosis mimicking inflammatory breast carcinoma. ( 28744985 )
2017
2
Gadolinium-Naive Nephrogenic Systemic Fibrosis of Breast Mimicking Inflammatory Breast Carcinoma. ( 28323787 )
2017
3
Idiopathic granulomatous mastitis mimicking inflammatory breast carcinoma: What are the odds? ( 27790396 )
2016
4
Cutaneous metastasis of inflammatory breast carcinoma mimicking an erythema annulare centrifugum: a sign of locally recurrent cancer. ( 27766674 )
2016
5
Axillary lymph node tuberculosis masquerading as inflammatory breast carcinoma in an immune-compromised patient. ( 25681261 )
2015
6
Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides. ( 26345728 )
2015
7
Primary Neuroendocrine Carcinoma of the Breast with Clinical Features of Inflammatory Breast Carcinoma: A Case Report and Literature Review. ( 26770249 )
2015
8
Axillary high-grade B-cell non-Hodgkin lymphoma presenting under the guise of inflammatory breast carcinoma. ( 26670406 )
2015
9
Breast filariasis or inflammatory breast carcinoma? Reaching a diagnosis. ( 26567240 )
2015
10
Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies. ( 25417171 )
2015
11
Collision tumor with inflammatory breast carcinoma and malignant phyllodes tumor: a case report and literature review. ( 24400686 )
2014
12
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. ( 24516025 )
2014
13
Comparison between invasive breast cancer with extensive peritumoral vascular invasion and inflammatory breast carcinoma: a clinicopathologic study of 161 cases. ( 25125618 )
2014
14
Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib. ( 24201163 )
2013
15
Inflammatory breast carcinoma. ( 23945485 )
2013
16
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. ( 24156086 )
2013
17
Inflammatory breast carcinoma. ( 23543972 )
2013
18
Unusual dermal pleomorphic calcifications in a case of inflammatory breast carcinoma. ( 24082417 )
2013
19
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? ( 21850396 )
2011
20
A woman with multiple silicone rupture complicated by inflammatory breast carcinoma. ( 21443069 )
2011
21
Inflammatory breast carcinoma and locally advanced breast carcinoma: characterisation with MR imaging. ( 20927653 )
2011
22
Gastric cancer in a pregnant woman presenting with low back pain and bilateral erythematous breast hypertrophy mimicking primary inflammatory breast carcinoma. ( 21378356 )
2011
23
p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma. ( 21252573 )
2011
24
A case of inflammatory breast carcinoma: carcinoma erysipeloides. ( 20228568 )
2010
25
Image of the month. Inflammatory breast carcinoma. ( 20157092 )
2010
26
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report. ( 20133250 )
2010
27
Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. ( 20503411 )
2010
28
Intravascular ALK-positive anaplastic large-cell lymphoma mimicking inflammatory breast carcinoma. ( 19364961 )
2009
29
Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma. ( 19082616 )
2009
30
Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth. ( 19707200 )
2009
31
Triple negative phenotype and N-ratio are important for prognosis in patients with stage IIIB non-inflammatory breast carcinoma. ( 19798691 )
2009
32
Fallopian tube cancer presenting as inflammatory breast carcinoma: report of a case and review of the literature. ( 19899419 )
2009
33
Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. ( 18206620 )
2008
34
Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis. ( 18308143 )
2008
35
Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. ( 18523781 )
2008
36
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. ( 17242702 )
2007
37
Nephrogenic systemic fibrosis mimicking inflammatory breast carcinoma. ( 17227116 )
2007
38
Metastatic esophageal carcinoma masquerading as inflammatory breast carcinoma. ( 17343591 )
2007
39
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. ( 16444747 )
2006
40
[Biological significance of E-cadherin in an inflammatory breast carcinoma cell line]. ( 16737610 )
2006
41
Docetaxel administered during pregnancy for inflammatory breast carcinoma. ( 16595038 )
2006
42
Unique features of inflammatory breast carcinoma. ( 16094760 )
2005
43
Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. ( 16278382 )
2005
44
Imaging in inflammatory breast carcinoma. ( 16735786 )
2005
45
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. ( 15998949 )
2005
46
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. ( 15143076 )
2004
47
Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. ( 14983486 )
2004
48
Do younger women with non-metastatic and non-inflammatory breast carcinoma have poor prognosis? ( 14736343 )
2004
49
Inflammatory breast carcinoma: the sphinx of breast cancer research. ( 14722054 )
2004
50
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. ( 15329897 )
2004

Variations for Inflammatory Breast Carcinoma

Expression for Inflammatory Breast Carcinoma

Search GEO for disease gene expression data for Inflammatory Breast Carcinoma.

Pathways for Inflammatory Breast Carcinoma

Pathways related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.18 CDH1 EGFR ERBB2
2
Show member pathways
12.12 CDH1 EGFR ERBB2 ESR1 PGR
3
Show member pathways
11.98 EGFR ERBB2 ESR1
4 11.94 EGFR ERBB2 ESR1
5 11.77 CDH1 EGFR ESR1
6
Show member pathways
11.47 EGFR ERBB2 ESR1
7 11.3 CDH1 EGFR ERBB2
8 11.23 EGFR ESR1
9 11.19 EGFR ERBB2
10 11.19 CDH1 EGFR ERBB2
11 11.13 CDH1 EGFR
12 10.97 EGFR ERBB2
13
Show member pathways
10.96 EGFR ERBB2 ESR1 PGR
14 10.71 CDH1 EGFR
15 10.62 CDH1 EGFR ERBB2

GO Terms for Inflammatory Breast Carcinoma

Biological processes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular response to epidermal growth factor stimulus GO:0071364 9.4 EGFR ERBB2
2 cellular response to estradiol stimulus GO:0071392 9.37 EGFR ESR1
3 ERBB2 signaling pathway GO:0038128 9.32 EGFR ERBB2
4 regulation of cell motility GO:2000145 9.26 EGFR ERBB2
5 positive regulation of transcription, DNA-templated GO:0045893 9.26 CDH1 EGFR ESR1 PROX1
6 regulation of ERK1 and ERK2 cascade GO:0070372 9.16 EGFR ERBB2
7 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 core promoter sequence-specific DNA binding GO:0001046 9.32 ESR1 PROX1
2 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.26 ESR1 PGR
3 steroid binding GO:0005496 9.16 ESR1 PGR
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR ERBB2
5 nitric-oxide synthase regulator activity GO:0030235 8.62 EGFR ESR1

Sources for Inflammatory Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....